Nilkamal Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 18, 2025
NILKAMAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nilkamal's board approved audited financial results for Q4 and FY25 (ended March 31, 2025) with an unmodified auditor opinion from S R B C & Co LLP. Standalone revenue from operations rose modestly to Rs. 3,239.3 crore (vs Rs. 3,134.1 crore in FY24), but standalone net profit declined ~15% to Rs. 91.27 crore (vs Rs. 107.31 crore). Consolidated net profit fell to Rs. 106.8 crore from Rs. 122.4 crore. Standalone EPS dropped to Rs. 61.16 from Rs. 71.91. The board recommended a final dividend of Rs. 20 per share (200%) subject to shareholder approval. The company will acquire the healthcare business of Imedfurns Private Limited for Rs. 4 crore (payable over 4 years). The 39th AGM is scheduled for July 18, 2025 via video conferencing.
Despite stable top-line growth, the ~15% drop in standalone profit and weaker retail/ecommerce segment (loss of Rs. 34.5 crore) may pressure the stock, though a consistent 200% dividend provides income support. The small Imedfurns healthcare acquisition (Rs. 4 crore) signals a diversification move but is not material to financials.